Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bone marrow derived CD271+ precursor cells
- Development stage
- Preclinical
- Lead developer
- Longeveron
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal, Intravenous
01
Overview
Bone marrow derived CD271+ precursor cells are an autologous cell therapy consisting of mesenchymal stem cells (MSCs) isolated from a patient's own bone marrow. The isolation process utilizes immunomagnetic selection targeting the CD271 (Low-affinity Nerve Growth Factor Receptor/p75NTR) surface marker, which identifies a specific subpopulation of MSCs with superior proliferative capacity, immunosuppressive activity, and cytokine production compared to standard adherence-based MSCs. This therapy is primarily investigated for neurological conditions such as drug-resistant epilepsy, spinal cord injury, and various encephalopathies, where it is thought to exert neuroprotective and regenerative effects through the secretion of trophic factors and immunomodulation. The technology for this CD271-specific cellular therapy is licensed to Longeveron.
- Other names
- CD271+ bone marrow mesenchymal stem cellsBMMSCsCD271+ BMMSCsautologous CD271+ mesenchymal stem cellsLNGFR+ bone marrow mesenchymal stem cellsp75NTR+ bone marrow mesenchymal stem cells
Beyond the preview
Go deeper on bone marrow derived CD271+ precursor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bone marrow derived CD271+ precursor cells.